iProXProteomicsYubo ZhouHomo Sapienshttp://www.iprox.org/page/project.html?id=IPX0018186000ybzhou@simm.ac.cnZhongshan Institute for Drug DiscoveryiProXfalseDiscovery of Selective and Potent BRPF1 Dege-reraders for the Treatment of Endocrine-sensitive Breast CancerESR1 mutations and activation of growth factor signaling (e.g., PI3K-AKT) drive endocrine therapy resistance in breast cancer, largely limiting the success of breast cancer treatment. We reported a first-in-class, selective and potent BRPF1-targeted proteolysis-targeting chimera (PROTAC) B-8, and it downregulated H3K23ac and ER, causing cell cycle arrest and autophagic cell death.Mon Jul 06 00:00:00 GMT+01:00 2026PXD0806509606